The variability in the impact of APOE ε4 on AD across African populations could be attributed to unique genetic variants or environmental factors that modulate AD risk differently than in other global populations.[17–19] For instance, earlier studies have suggested a significant correlation between APOE ε4 homozygosity and AD in certain populations such as Yoruba.[20,21] This diversity underscores the importance of expanding genetic studies in underrepresented populations to uncover novel insights that could provide more effective and personalized treatments for AD. The gene discussed is APOE; the disease is Alzheimer disease.